INTRODUCTION
Cancer metastasis is a multistep and complex process that involves dissociation of the tumor cells from the organ of origin, degradation of the extracellular matrix (ECM), cell migration, anchorage-independent growth, apoptosis evasion, angiogenesis, invasion of surrounding tissues, cell adhesion, movement and colonization to distant sites in the body 1 . Human prostate cancer progression to advanced metastatic disease is associated with relapse to a hormone-refractory state due to impaired apoptotic response to androgen ablation. Androgen-independent prostate cancer cells become resistant due to roadblocks in apoptosis and depending on the interactions with the tumor microenvironment, acquire invasive and metastatic properties 2 . Both tumor epithelial and endothelial cells require attachment to the ECM for survival; commonly upon loss of adhesion, cells undergo detachment-induced cell death, or anoikis. Anoikis, a unique phenomenon of apoptosis consequential to insufficient cell-matrix interactions 3, 4 , is recognized as a significant player in tumor angiogenesis and metastasis 5 . During metastatic progression, cells are in a dynamic state lacking firm attachment to the ECM and susceptible to anoikis 5 .
Resistance to die via anoikis dictates tumor cell survival and provides a molecular basis for therapeutic targeting of metastatic prostate cancer. Integrin-linked kinase (ILK) has been recognized as contributor to anoikis resistance via its ability to regulate several integrin-mediated cellular processes including cell adhesion, fibronectin-ECM assembly and anchorage-dependent cell growth [6] [7] [8] .
Integrins are cell membrane receptors that mediate the functional interactions between a cell and the ECM, thus serving as bidirectional transducers of extracellular and intracellular signals, ultimately regulating adhesion, proliferation, anoikis, survival and tumor progression [9] [10] [11] [12] . Talin1 is a cytoskeletal linker protein that interacts with the cytoplasmic domain of integrins leading to integrin activation 10, 13 and regulates their adhesion to extracellular ligands 14 . Talin1-deficient mice exhibit failure of integrins to aggregate into clusters and connect to the cytoskeleton, resembling the integrin deficient phenotype, and supporting that integrin function is talin1-dependent 15 . Furthermore recent studies in Drosophila, demonstrate that talin1 suppresses E-cadherin expression independent of integrin 16 , indicating a role for talin1 distinct from the integrin-dependent mechanism. The contribution of talin1 to cancer development and progression has not previously investigated.
The present study investigated the role of talin1 in prostate cancer progression to metastasis. Our results indicate that talin1 engages the PI3-K/AKT signaling as the intracellular survival mechanism to confer anoikis resistance and promote invasion of human prostate cancer cells. Moreover, talin1 profiling in human prostate cancer specimens revealed a significantly increase in talin1 expression in metastatic prostate compared to benign and primary prostate tumors.
RESULTS
The effect of talin1 overexpression on the adhesion ability and migration potential of prostate cancer cells were first examined in vitro. GFP-talin1 stable transfectants of human PC-3 prostate cancer cells were generated, since this cell line expressed very low endogenous talin1 levels (Fig. 1A , and Sup1). Overexpression of talin1 significantly increased both the adhesion (Fig. 1B) and migration potential of prostate cancer cells compared to vector control cells (Fig. 1 , panels C, D). We subsequently determined the consequences of talin1-overexpression on the invasion potential of prostate cancer cells through an endothelial cell monolayer. The trans-endothelial migration (TEM) assay was performed using the human brain membrane endothelial cells (HBMEC). Talin1 overexpression led to a significantly increased prostate cancer cell invasion through endothelial cell monolayer (Fig. 1 , panels E and F).
Prostate tumor epithelial cell survival requires continuous attachment to the ECM and it is recognized that fibronectin, laminin and collagen participate in the formation of attachment plagues linked to the actin cytoskeleton. (Fig. 2B ). Furthermore loss of talin1 led to significant reduction in the migration potential compared to vector control cells (Fig. 2 , panels C and D).
Examination of the invasion ability of talin1-silenced transfectants through an endothelial cell monolayer revealed a significant suppression (Fig. 2 , panels E and F).
The mechanism via which talin1 activates intracellular signals was subsequently examined in the context ECM-epithelial cell interaction. We focused on the FAK/AKT and the intracellular MAP kinase signaling pathway, as both mechanisms have been implicated in integrin-focal adhesion dependent signals 17 . Activation of FAK due to phosphorylation (Y397) was observed on collagen attachment conditions, while it was more prominent on fibronectin coated ECM in talin1 overexpressing cells relative to control cells (Fig. 3A) . Talin1 overexpression also resulted in a marked activation on phosphorylation of AKT (Ser473) under fibronectin-attachment conditions, while only a modest activation of p44/42 MAP kinase was observed (Fig. 3A) . The expression level of integrin-dependent signals was confirmed by confocal microscopy (Fig. 3B ). Talin1 overexpressing cells exhibited increased expression of P-FAK, P-AKT and P-MAPK proteins relative to vector control cells upon fibronectin-aatachment conditions (Fig. 3B ).
Furthermore, talin1 overexpression enhanced AKT phosphorylation within the first 3hrs of incubation (Fig. 3 , panels C, D), an change that temporally preceded a significant increase in phosphorylated FAK and MAPK (Fig. 3C, D) .
The effect of talin1 on integrin-focal adhesion complex signaling interactions was subsequently investigated, by examining the direct binding of talin1 to integrn β3, a key talin1 binding partner 18 . To this end we used the DU-145 cell line, which exhibits high endogenous expression of integrin β3 (data not shown). Talin1 silencing significantly reduced the protein binding to integrin β3, as well as the focal adhesion partners, FAK and SRC (Fig. 3E) . The reduced binding of SRC upon talin1 loss, led us to determine the role of ILK-1, a protein that regulates SRC binding in response to integrin activation (Fig. 3F ). Immunoprecipitation by integrin β3 revealed a significant decrease in ILK-1 interaction in talin1-silenced prostate cancer cells.
Immunoprecipitation by ILK-1 also revealed a similar pattern, indicating that talin1 loss inhibited ILK-1 binding to integrin β3 complex (Fig. 3F ).
In view of the emerging role of anoikis resistance as a critical contributor to metastasis during cancer progression 5 To determine whether AKT activation is an integral part of talin1 intracellular signaling, the consequences of AKT inhibition on talin1-mediated biological effects were examined. Since AKT activation comprises a critical signaling effector in anoikis resistance 21 we next studied the impact of talin1 overexpression on anoikis. The data on while the intensity of talin1 staining was stronger in primary prostate tumors, with the highest detected in liver metastases (Fig. 6 ii). Quantitative analysis revealed a 2-fold increase in talin1 expression in prostate tumors derived from 12wk TRAMP mice, compared to the 6wk old TRAMP prostates (Table 1) . By 27 wks of age, upon time TRAMP mice exhibit a highly aggressive prostate tumor phenotype (grade 4.5-5), talin1
immunoreactivity increased dramatically (Fig. 6 ), a change that reached a statistical significance (<0.01, Table 1 ).
To determine whether talin1 might have a potential value for predicting human prostate cancer progression to metastastic disease, we conducted an immunohistochemical staining for talin1 in human prostate tissue specimens. Talin1 expression was analyzed in human prostate tissue specimens from normal, BPH, primary tumors (Gleason 6-9) and metastatic tumors ( Table 2 ). Detection of immunoreactivity was followed by automated quantitative analysis to measure the cytoplasmic levels of talin1. A representative picture of normal prostate, BPH, primary prostate tumor and metastatic lesion to the lymph node is shown on Figure 7 (Panel A). Cytoplasmic talin1 was significantly higher in metastases than in primary tumors and both were significantly elevated compared to normal prostate tissue (P<0.0001, P<0.0001, respectively). These findings suggest that talin1 expression is positively associated with human prostate cancer progression to metastatic disease. Normal areas of prostate adjacent to tumor foci expressed lower talin1 levels compared to the remaining normal prostate tissue (Table 1 ).
Talin1 expression detected in BPH specimens was comparable to those detected in normal prostate tissue.
DISCUSSION
The present study identifies talin1 as a novel regulator of prostate cancer cell invasion and metastatic potential, via its ability to enhance survival signals and confer anoikis resistance. Several key survival signaling pathways including AKT, FAK and Ras/Erk are activated by integrin adhesion and detachment from the ECM results in their inactivation 17 . Anoikis, (detachment from the ECM), results in activation of pro-apoptotic proteins and inhibition of anti-apoptotic proteins 22, 23 . Our findings demonstrate that talin1 overexpression significantly enhanced the migration and invasion potential of human prostate cancer cells via an AKT-dependent mechanism. In contrast, loss of talin1 led to a diminished invasion potential and in vivo metastatic ability of prostate cancer cells.
These results are in accord with a previous screening reporting that highly metastatic cells expressed significantly high levels of talin1 (>16 fold, out of 440 proteins screened) compared to less metastatic cells 24 . Interestingly enough, in primary prostate cancer cells, talin1 mRNA has been shown to be downregulated by androgens 25 . Taken together this evidence supports an indirect link between talin1 and prostate cancer metastasis and emergence to androgen-independence.
Overexpressing talin1 in prostate cancer cells led to activation of FAK/AKT signaling via both an ECM-dependent and -independent mechanism. Gaining strong support from evidence that AKT survival signaling is causally linked to anoikis resistance in detached cells 26, 27 , our data indicate that talin1 promotes prostate cancer cells to metastasize by enhancing their invasive properties and survival after detachment from the primary tumor site via activation of FAK and AKT signaling. This resonates with a similar role assigned to another key focal adhesion protein, paxillin in different tumors.
Indeed, overexpression of paxillin correlates with metastatic and invasion properties in hepatocellular carcinoma 28 . Recruitment of FAK and paxillin to β1 integrin promotes cancer cell migration through MAPK activation 29 . The present findings suggest that talin1 might not be causally involved in primary tumor development, but rather in promoting local invasion, as well as distant metastasis, via conferring resistance to in PBS for image analysis. Cells were counted in three x100 fields/well.
Migration Assay:
Cell cultures (at 75% confluency) were subjected to wounding as previously described 32 . At 24 and 48hrs post-wounding cells migrating to the wounded areas were counted under the microscope. Cell Cycle Arrest-Flow Cytometric Analysis: Cells were fixed with 70%
ethanol (30mins at 4°C) and were subsequently stained with Propidium iodide (50μg/ml) containing 20μg/ml of RNase (30mins at room temperature). Cell cycle progression was analyzed via fluorescence-activated cell sorting (FACS) using the Partec Flow Max.
Anoikis Evaluation: Cells were plated on dishes coated with either fibronectin or the nonadhesive polyhydroxyethylmethacrylate (poly-HEMA) and incubated for 24hr.
Cells undergoing apoptosis were detected using the Annexin V immunofluorescence approach and flow-cytometric analysis. Western blotting was used to determine the expression of key apoptosis regulators after overexpression and silencing of talin1 in prostate cancer cells.
In Vivo Experimental Metastasis Assay:
Human prostate cancer cells were injected (2x10 6 cells /80μl of PBS) in the tail vein of male nude mice (4-6 wks). After 5-weeks mice were sacrificed and the lungs and liver were surgically excised and examined for metastatic lesions under a dissecting microscope (40x).
TRAMP Transgenic Mouse Model:
The TRAMP mice (C57BL/6J) are transgenic mice that express SV40T/t antigens under the prostate specific rat probasin promoter 34, 35 . TRAMP transgenic males develop prostate adenocarcinoma in a manner resembling the clinical progression of human prostate cancer from intra-epithelial neoplasia to androgen-independent metastatic tumors. Histological hematoxylin and eosin (H&E) sections of prostate tissues from TRAMP/+/+ male mice were evaluated by two independent investigators (S.S. and N.K.) to confirm the pathological grade. Wildtype male mice (C57BL/6) of comparable age groups (6-29wks) served as controls. The histopathological grading of prostatic tumors was conducted using a standard grading scale in TRAMP mice. Flat lesions and focal cell piling (grade 2.0-2.2) were observed in the majority of 12wks-old TRAMP mice (Table 1 ). In 20wk-27wk-old TRAMP mice, prostates exhibited focal cribriform lesions protruding into the lumen (grade 3-5),
representing tumor progression to advanced disease.
Prostate serial sections from the normal wild type and the TRAMP tumors of increasing grade and metastatic lesions (5μm), were subjected to immunohistochemical analysis for talin1 using the talin1 polyclonal antibody (generously provided by Dr. Blue represents DAPI nuclear staining. Panel B, mRNA expression profiling. RNA samples from the various human prostate tumor epithelial cells were subjected to reverse transcription, and subsequent PCR using talin1 and 18S primers as described in "Materials and Methods". Talin1 mRNA expression was normalized to 18S expression.
